Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -122.55% | -7.03% | -45.51% | -11.91% | 26.58% |
| Total Depreciation and Amortization | 33.58% | 66.67% | 31.90% | 24.33% | 32.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 681.99% | -80.07% | 65.73% | 472.61% | 170.54% |
| Change in Net Operating Assets | -140.72% | 135.90% | 48.12% | -382.85% | -89.69% |
| Cash from Operations | -62.87% | 55.77% | -8.05% | 2.18% | -0.13% |
| Capital Expenditure | -336.34% | -42.79% | -1,438.89% | -2,385.29% | 10.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -341.32% | -42.79% | -1,038.98% | -2,385.29% | 11.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -95.30% | -- | -- | -98.15% | 120,550.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -95.30% | 1,706.02% | 105.31% | -98.14% | 528,751.67% |
| Foreign Exchange rate Adjustments | 102.66% | -176.75% | 239.01% | 120.72% | -262.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -134.35% | 572.17% | 38.93% | -134.09% | 568.04% |